Presentation Topic

Presenter

Date

Content

Pharmacogenomics in Stroke Precision Medicine

Dr. Guillaume Paré

10/8/2024

The Future of Cerebroprotection After MOST and Nerinetide

Patrick Lyden, MD

3/18/2024

Translation of Stroke Neurorehabilitation from Animals to Patients

Sean l Savitz, MD

10/23/2023

Candidate Pharmacological Therapies for Stroke Recovery

S. Thomas Carmichael, MD, PhD

11/17/2022

TRANSPORT2 Study on the StrokeNet Science and Beyond Science

Wayne Feng, MD

8/22/2022

Intracranial Athero and Vascular Remodeling associated with the upcoming CAPTIVA Trial

Jose Gutierrez, MD

5/4/2022

Cell Based Regenerative Therapies for Stroke

Sean Savitz, MD

4/28/2022

Quality Data Management in Clinical Trials

Catherine Dillon, MS

10/14/2021

Basic Science Underpinnings of Childhood Stroke

Heather Fullerton, MD

12/8/2020

A Failure of Forward Translation? The Case of Neuroprotection

Jin-Moo Lee, MD

11/19/2020

The Science Underlying the Most Trial

Joseph Broderick, MD

7/24/2019

Preconditioning the Brain for Stroke Prevention

Sebastian Koch, MD & Miguel Perez-Pinzon, PhD

4/4/2019

Genomics as an Informational Tool in Neurorehabilitation

Steven Cramer, MD

7/26/2018

Cerebral Hemodynamics and Cognition

References:

Brain blood flow restoration 'rescues' chronically damaged rat CA1 neurons. de la Torre, Fortin, Park, Pappas. Brain Research 1993, 623:6-15.

Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration. Balestrini S, Perozzi C, Altamura C, et al. Neurology 2013;80;2145-2150.

Randolph Marshall, MD

3/15/2018

ARCADIA – A Stroke Story

Reference:

Longstreth WT, Jr., Kronmal RA, Thompson JL, Christenson RH, et al. Brain Research 1993, 623:6-15. Amino Terminal Pro-B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy. Stroke. 2013;44(3):714-9.

David Tirschwell, MD

12/20/2017